FDA Refuse-To-File Letter For Alkermes Depression Drug Suggests A Lengthy Commercial Delay

CEO Richard Pops called FDA's letter for ALKS 5461 "surprising and troubling." Alkermes had been ramping up to launch the depression drug later this year, though some investors had remained skeptical.

Accept - Refuse_529502731_1200.jpg

More from New Products

More from Scrip